Table 1.
Association of miR-21 expression with clinicopathological features.
| Variable | N | Serum miR-21 | p | PBMC miR-21 | p |
|---|---|---|---|---|---|
| Clinical stage | |||||
| I | 9 | 32.31 (22.88–54.12) | 0.790 | 33.01 (22.35–53.63) | 0.751 |
| II | 11 | 31.62 (21.14–50.12) | 32.42 (21.05–51.79) | ||
| III | 10 | 31.43 (22.31–49.33) | 31.38 (21.31–49.98) | ||
| IV | 18 | 30.82 (23.45–41.23) | 30.19 (20.45–45.94) | ||
| Age | |||||
| <35 | 8 | 31.77 (23.28–51.02) | 0.812 | 30.33 (22.43–50.78) | 0.892 |
| 35–50 | 10 | 29.67 (23.21–50.53) | 28.66 (24.32–51.22) | ||
| 51–65 | 18 | 30.25 (24.22–52.38) | 30.66 (23.99–51.59) | ||
| >66 | 14 | 32.81 (25.88–53.62) | 31.67 (22.98–54.11) | ||
| Gender | |||||
| Male | 24 | 29.95 (23.24–49.38) | 0.844 | 28.66 (22.42–48.78) | 0.789 |
| Female | 26 | 30.17 (22.66–50.19) | 29.32 (23.16–50.68) | ||
| Lymphatic metastasis | |||||
| Yes | 27 | 29.99 (25.87–51.12) | 0.678 | 31.54 (24.55–51.66) | 0.643 |
| No | 23 | 30.23 (24.78–50.22) | 32.11 (24.11–50.35) | ||
| Differentiation degree | |||||
| Low | 12 | 29.87 (24.68–49.88) | 0.99 | 30.22 (23.33–51.66) | 0.89 |
| Middle | 17 | 30.19 (24.98–50.86) | 30.12 (23.02–51.76) | ||
| High | 21 | 30.21 (25.56–51.25) | 31.01 (24.45–51.87) | ||
| Surgery | |||||
| Yes | 24 | 30.55 (24.97–50.15) | 0.551 | 31.44 (24.29–51.54) | 0.521 |
| No | 26 | 29.78 (23.99–51.21) | 30.22 (23.12–50.18) |